Vancouver, BC, February 4, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that Ian Ball, Chief Commercial Officer, will transition to a full-time senior management role with the Company's partner, Medicom Healthcare in the UK, as of February 1st, 2020.

Vancouver, BC, January 21, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that a major health authority in British Columbia recently announced a change to their dispensing formulary for tacrolimus, an immunosuppressive drug that is used to prevent organ rejection after transplantation.

Vancouver, BC, January 13, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that it has advanced the filings for provincial reimbursement in both Quebec and British Columbia for its lead product, PrVistitanTM (bimatoprost 0.03%).

Vancouver, BC, December 30, 2019--Aequus Pharmaceuticals Inc.(TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced the signing of a term sheet to co-commercialize a portfolio of products in the USA with Medicom Healthcare, a United Kingdom based pharmaceutical company with a focus on preservative free therapies in ophthalmology.

Vancouver, BC, December 20, 2019--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, reported financial results for the three months ended September 30, 2019 ("Q3 2019") and associated Company developments.

Vancouver, BC, December 17, 2019--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced the signing of a term sheet to co-commercialize a portfolio of products in the USA with Medicom Healthcare, a United Kingdom based pharmaceutical company with a focus on preservative free therapies in ophthalmology.

Vancouver, BC, September 11, 2019--Aequus Pharmaceuticals Inc.(TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, reported financial results for the three months ended June 30, 2019 and associated Company developments.

Vancouver, BC, June 3, 2019--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, reported financial results for the three months ended March 31, 2019 ("Q1 2019") and associated Company developments. 

Vancouver, BC, May 7, 2019--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, reported financial results for the full year ended December 31, 2018. Unless otherwise noted, all figures are in Canadian currency.

Vancouver, BC, December 18, 2018--Aequus Pharmaceuticals Inc.(TSX-V: AQS) announced the signing of a term sheet for an exclusive license in Canada of an undisclosed preservative free ophthalmic therapeutic with a European partner. Aequus expects the preservative free therapeutic to achieve peak annual sales between $4M-$6M, with an expectation of revenue in excess of $35M to the Company throughout the duration of the license.